Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845582 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Study of ALK-001 in Geographic Atrophy
A Phase 2 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Alkeus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT03845582 is a Phase 2 study of Age-related Macular Degeneration and Geographic Atrophy that has completed, run by Alkeus Pharmaceuticals. The registered enrollment target is 200 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03845582, a Phase 2 study of Age-related Macular Degeneration and Geographic Atrophy, has completed, sponsored by Alkeus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG ALK-001 oral capsule
Study Locations (20)
Florida
- Alkeus Site - Clearwater
- Alkeus Site - Fort Myers
- Alkeus Site - Gainesville
- Alkeus Site - Tampa
- Alkeus Site - Winter Haven
New York
- Alkeus Site - Great Neck
- Alkeus Site - Hauppauge
Arizona
- Alkeus Site - Phoenix
California
- Alkeus Site - Beverly Hills
Colorado
- Alkeus Site - Lakewood
Illinois
- Alkeus Site - Bloomington
Kentucky
- Alkeus Site - Lexington
Maryland
- Alkeus Site - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845582
The ClinicalTrials.gov registry entry for NCT03845582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (87% lower). The listed sponsor is Alkeus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03845582 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT03845582 about?
NCT03845582 is a clinical study titled "Phase 2/3 Study of ALK-001 in Geographic Atrophy". This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participan...
What is the current status of trial NCT03845582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2019-05-07. Estimated completion is 2024-06-30.
What conditions does trial NCT03845582 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy, AMD, Atrophy, Geographic.
What interventions are being tested in trial NCT03845582?
The interventions under investigation include: Placebo oral capsule (DRUG), ALK-001 oral capsule (DRUG).
Who is sponsoring clinical trial NCT03845582?
This trial is sponsored by Alkeus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845582 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.